Autoinhibition of c-Abl.

Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood (2008) 2.76

Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. Mol Cell Biol (2006) 2.28

Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc Natl Acad Sci U S A (2002) 2.13

ABL tyrosine kinases: evolution of function, regulation, and specificity. Sci Signal (2010) 1.91

Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain. Mol Biol Cell (2003) 1.79

Regulation of cell migration and morphogenesis by Abl-family kinases: emerging mechanisms and physiological contexts. J Cell Sci (2009) 1.78

RNA interference screen identifies Abl kinase and PDGFR signaling in Chlamydia trachomatis entry. PLoS Pathog (2008) 1.63

Two distinct phosphorylation pathways have additive effects on Abl family kinase activation. Mol Cell Biol (2003) 1.50

T cell receptor-independent basal signaling via Erk and Abl kinases suppresses RAG gene expression. PLoS Biol (2003) 1.49

Functional anthology of intrinsic disorder. 2. Cellular components, domains, technical terms, developmental processes, and coding sequence diversities correlated with long disordered regions. J Proteome Res (2007) 1.48

Conformational disturbance in Abl kinase upon mutation and deregulation. Proc Natl Acad Sci U S A (2009) 1.47

Enteropathogenic Escherichia coli use redundant tyrosine kinases to form actin pedestals. Mol Biol Cell (2004) 1.32

Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance. Proc Natl Acad Sci U S A (2006) 1.30

Mechanisms of drug resistance in kinases. Expert Opin Investig Drugs (2011) 1.29

Werner syndrome protein phosphorylation by abl tyrosine kinase regulates its activity and distribution. Mol Cell Biol (2003) 1.23

Caspase-dependent cleavage of c-Abl contributes to apoptosis. Mol Cell Biol (2003) 1.20

BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib. Blood (2010) 1.19

Oncogenic activation of c-Abl in non-small cell lung cancer cells lacking FUS1 expression: inhibition of c-Abl by the tumor suppressor gene product Fus1. Oncogene (2007) 1.15

Hierarchical modeling of activation mechanisms in the ABL and EGFR kinase domains: thermodynamic and mechanistic catalysts of kinase activation by cancer mutations. PLoS Comput Biol (2009) 1.15

Type IV secretion in the obligatory intracellular bacterium Anaplasma phagocytophilum. Cell Microbiol (2010) 1.07

Tr-kit-induced resumption of the cell cycle in mouse eggs requires activation of a Src-like kinase. EMBO J (2002) 1.07

A crucial role in cell spreading for the interaction of Abl PxxP motifs with Crk and Nck adaptors. J Cell Sci (2008) 1.06

The Hippo pathway kinase Lats2 prevents DNA damage-induced apoptosis through inhibition of the tyrosine kinase c-Abl. Cell Death Differ (2013) 1.04

NMR reveals the allosteric opening and closing of Abelson tyrosine kinase by ATP-site and myristoyl pocket inhibitors. Proc Natl Acad Sci U S A (2013) 1.03

Cbl-ArgBP2 complex mediates ubiquitination and degradation of c-Abl. Biochem J (2003) 1.01

The Abl SH2-kinase linker naturally adopts a conformation competent for SH3 domain binding. Protein Sci (2007) 1.01

Structure and dynamic regulation of Abl kinases. J Biol Chem (2013) 1.01

Altered subcellular distribution of c-Abl in Alzheimer's disease. J Alzheimers Dis (2009) 0.99

A peptide biosensor for detecting intracellular Abl kinase activity using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Anal Biochem (2009) 0.99

Extracellular vesicle-mediated transfer of donor genomic DNA to recipient cells is a novel mechanism for genetic influence between cells. J Mol Cell Biol (2013) 0.98

Allosteric inhibition of the nonMyristoylated c-Abl tyrosine kinase by phosphopeptides derived from Abi1/Hssh3bp1. Biochim Biophys Acta (2008) 0.96

A solid-phase Bcr-Abl kinase assay in 96-well hydrogel plates. Anal Biochem (2007) 0.96

Enhancement of ABL kinase catalytic efficiency by a direct binding regulator is independent of other regulatory mechanisms. J Biol Chem (2008) 0.96

Intracellular retention of ABL kinase inhibitors determines commitment to apoptosis in CML cells. PLoS One (2012) 0.95

Tyrosine phosphorylation in the SH3 domain disrupts negative regulatory interactions within the c-Abl kinase core. J Mol Biol (2008) 0.95

Abl N-terminal cap stabilization of SH3 domain dynamics. Biochemistry (2008) 0.95

Threshold levels of ABL tyrosine kinase inhibitors retained in chronic myeloid leukemia cells determine their commitment to apoptosis. Cancer Res (2013) 0.94

Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders. Leukemia (2008) 0.93

c-Abl antagonizes the YAP oncogenic function. Cell Death Differ (2014) 0.92

Enhanced resistance to tamoxifen by the c-ABL proto-oncogene in breast cancer. Neoplasia (2010) 0.92

SHP-2 phosphatase is required for hematopoietic cell transformation by Bcr-Abl. Blood (2006) 0.91

Transferred BCR/ABL DNA from K562 extracellular vesicles causes chronic myeloid leukemia in immunodeficient mice. PLoS One (2014) 0.91

Structure, regulation, signaling, and targeting of abl kinases in cancer. Genes Cancer (2012) 0.90

c-Abl phosphorylation of ΔNp63α is critical for cell viability. Cell Death Dis (2010) 0.90

Interplay between kinase domain autophosphorylation and F-actin binding domain in regulating imatinib sensitivity and nuclear import of BCR-ABL. PLoS One (2011) 0.90

Cancer-associated mutations activate the nonreceptor tyrosine kinase Ack1. J Biol Chem (2010) 0.89

Activation of abl family kinases in solid tumors. Genes Cancer (2012) 0.89

Angiotensin-II and MARCKS: a hydrogen peroxide- and RAC1-dependent signaling pathway in vascular endothelium. J Biol Chem (2012) 0.87

Partial cooperative unfolding in proteins as observed by hydrogen exchange mass spectrometry. Int Rev Phys Chem (2013) 0.87

Galectin-3: A novel substrate for c-Abl kinase. Biochim Biophys Acta (2010) 0.85

ABL fusion oncogene transformation and inhibitor sensitivity are mediated by the cellular regulator RIN1. Leukemia (2010) 0.85

High CC chemokine receptor 7 expression improves postoperative prognosis of lung adenocarcinoma patients. Br J Cancer (2013) 0.85

Intramolecular dynamics within the N-Cap-SH3-SH2 regulatory unit of the c-Abl tyrosine kinase reveal targeting to the cellular membrane. J Biol Chem (2013) 0.82

Protein kinase G increases antioxidant function in lung microvascular endothelial cells by inhibiting the c-Abl tyrosine kinase. Am J Physiol Cell Physiol (2014) 0.81

The SH2 domain regulates c-Abl kinase activation by a cyclin-like mechanism and remodulation of the hinge motion. PLoS Comput Biol (2014) 0.80

Misfolding, Aggregation, and Disordered Segments in c-Abl and p53 in Human Cancer. Front Oncol (2015) 0.79

MicroRNA-4723 inhibits prostate cancer growth through inactivation of the Abelson family of nonreceptor protein tyrosine kinases. PLoS One (2013) 0.77

Functional mechanisms and roles of adaptor proteins in abl-regulated cytoskeletal actin dynamics. J Signal Transduct (2012) 0.77

Fluorescence Polarization Screening Assays for Small Molecule Allosteric Modulators of ABL Kinase Function. PLoS One (2015) 0.76

Conformational transition of FGFR kinase activation revealed by site-specific unnatural amino acid reporter and single molecule FRET. Sci Rep (2017) 0.75

Heterogeneity of BCR-ABL rearrangement in patients with chronic myeloid leukemia in Pakistan. Pak J Med Sci (2014) 0.75

Functional organization of the yeast proteome by systematic analysis of protein complexes. Nature (2002) 45.19

Proteome survey reveals modularity of the yeast cell machinery. Nature (2006) 20.77

Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med (2013) 9.65

The minimum information required for reporting a molecular interaction experiment (MIMIx). Nat Biotechnol (2007) 8.24

An orthogonal proteomic-genomic screen identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome. Nat Immunol (2009) 7.93

A physical and functional map of the human TNF-alpha/NF-kappa B signal transduction pathway. Nat Cell Biol (2004) 7.23

ELM server: A new resource for investigating short functional sites in modular eukaryotic proteins. Nucleic Acids Res (2003) 6.86

Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell (2003) 5.44

Peroxisomes are signaling platforms for antiviral innate immunity. Cell (2010) 5.24

The CRAPome: a contaminant repository for affinity purification-mass spectrometry data. Nat Methods (2013) 4.34

Human Proteinpedia enables sharing of human protein data. Nat Biotechnol (2008) 4.21

IFIT1 is an antiviral protein that recognizes 5'-triphosphate RNA. Nat Immunol (2011) 4.18

Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood (2007) 3.59

A myristoyl/phosphotyrosine switch regulates c-Abl. Cell (2003) 3.48

An efficient tandem affinity purification procedure for interaction proteomics in mammalian cells. Nat Methods (2006) 3.38

Target profiling of small molecules by chemical proteomics. Nat Chem Biol (2009) 3.20

Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat Rev Mol Cell Biol (2004) 3.10

Structure-based assembly of protein complexes in yeast. Science (2004) 2.89

Complement factor H binds malondialdehyde epitopes and protects from oxidative stress. Nature (2011) 2.64

A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat Chem Biol (2010) 2.53

The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci U S A (2007) 2.51

Structural coupling of SH2-kinase domains links Fes and Abl substrate recognition and kinase activation. Cell (2008) 2.46

Rediscovering the sweet spot in drug discovery. Drug Discov Today (2003) 2.45

NSs protein of rift valley fever virus induces the specific degradation of the double-stranded RNA-dependent protein kinase. J Virol (2009) 2.39

Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase. Mol Cell (2006) 2.28

RhoB and actin polymerization coordinate Src activation with endosome-mediated delivery to the membrane. Dev Cell (2004) 2.13

Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis. Cell (2011) 2.11

Mass spectrometry-based functional proteomics: from molecular machines to protein networks. Nat Methods (2007) 2.06

c-Src-mediated phosphorylation of hnRNP K drives translational activation of specifically silenced mRNAs. Mol Cell Biol (2002) 1.98

Viral immune modulators perturb the human molecular network by common and unique strategies. Nature (2012) 1.86

Systems medicine and integrated care to combat chronic noncommunicable diseases. Genome Med (2011) 1.78

BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia. Nat Chem Biol (2012) 1.77

The DEAD-box helicase DDX3X is a critical component of the TANK-binding kinase 1-dependent innate immune response. EMBO J (2008) 1.76

Amputation-induced reactive oxygen species are required for successful Xenopus tadpole tail regeneration. Nat Cell Biol (2013) 1.72

Src kinase phosphorylates Caspase-8 on Tyr380: a novel mechanism of apoptosis suppression. EMBO J (2006) 1.64

CD14 is a coreceptor of Toll-like receptors 7 and 9. J Exp Med (2010) 1.64

Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leuk Lymphoma (2008) 1.63

SAMHD1 is a nucleic-acid binding protein that is mislocalized due to aicardi-goutières syndrome-associated mutations. Hum Mutat (2012) 1.61

Structural basis for viral 5'-PPP-RNA recognition by human IFIT proteins. Nature (2013) 1.58

A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domain. Nat Struct Mol Biol (2010) 1.47

Selective serotonin reuptake inhibitors--a new modality for the treatment of lymphoma/leukaemia? Biochem Pharmacol (2007) 1.44

c-Abl is an effector of Src for growth factor-induced c-myc expression and DNA synthesis. EMBO J (2002) 1.41

Charting the molecular network of the drug target Bcr-Abl. Proc Natl Acad Sci U S A (2009) 1.37

Transgenic mouse proteomics identifies new 14-3-3-associated proteins involved in cytoskeletal rearrangements and cell signaling. Mol Cell Proteomics (2006) 1.32

Interlaboratory reproducibility of large-scale human protein-complex analysis by standardized AP-MS. Nat Methods (2013) 1.30

Protein complexes and proteome organization from yeast to man. Curr Opin Chem Biol (2003) 1.30

Structural basis for the cytoskeletal association of Bcr-Abl/c-Abl. Mol Cell (2005) 1.21

Caspase-dependent cleavage of c-Abl contributes to apoptosis. Mol Cell Biol (2003) 1.20

BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib. Blood (2010) 1.19

General statistical modeling of data from protein relative expression isobaric tags. J Proteome Res (2011) 1.18

Initial characterization of the human central proteome. BMC Syst Biol (2011) 1.18

A complex prediction: three-dimensional model of the yeast exosome. EMBO Rep (2002) 1.18

Proteomic analysis of human cataract aqueous humour: Comparison of one-dimensional gel LCMS with two-dimensional LCMS of unlabelled and iTRAQ®-labelled specimens. J Proteomics (2010) 1.18

The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2). BMC Struct Biol (2009) 1.18

A reversible gene trap collection empowers haploid genetics in human cells. Nat Methods (2013) 1.17

Functional dissection of the TBK1 molecular network. PLoS One (2011) 1.16

FAM111A mutations result in hypoparathyroidism and impaired skeletal development. Am J Hum Genet (2013) 1.06

The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils. Blood (2008) 1.05

Mig6 is a sensor of EGF receptor inactivation that directly activates c-Abl to induce apoptosis during epithelial homeostasis. Dev Cell (2012) 1.04

The TLR-independent DNA recognition pathway in murine macrophages: Ligand features and molecular signature. Eur J Immunol (2009) 1.04

Antiinflammatory effects of tumor necrosis factor on hematopoietic cells in a murine model of erosive arthritis. Arthritis Rheum (2010) 1.03

Plk1-dependent phosphorylation of optineurin provides a negative feedback mechanism for mitotic progression. Mol Cell (2012) 1.02

Cytoplasmic Listeria monocytogenes stimulates IFN-beta synthesis without requiring the adapter protein MAVS. FEBS Lett (2006) 1.00

pTransgenesis: a cross-species, modular transgenesis resource. Development (2011) 0.99

Virulence factor NSs of rift valley fever virus recruits the F-box protein FBXO3 to degrade subunit p62 of general transcription factor TFIIH. J Virol (2014) 0.96

The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL. Cancer Res (2012) 0.95

A method to resolve the composition of heterogeneous affinity-purified protein complexes assembled around a common protein by chemical cross-linking, gel electrophoresis and mass spectrometry. Nat Protoc (2012) 0.95

KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib. Blood (2011) 0.94

Characterisation of a new regulator of BDNF signalling, Sprouty3, involved in axonal morphogenesis in vivo. Development (2010) 0.94

Phosphorylation of Bruton's tyrosine kinase by c-Abl. Biochem Biophys Res Commun (2002) 0.93

MASPECTRAS 2: An integration and analysis platform for proteomic data. Proteomics (2010) 0.93

Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms. Mol Syst Biol (2013) 0.93

Temporal and spatial expression of FGF ligands and receptors during Xenopus development. Dev Dyn (2009) 0.92

An integrated chemical biology approach identifies specific vulnerability of Ewing's sarcoma to combined inhibition of Aurora kinases A and B. Mol Cancer Ther (2011) 0.91

Regulation of c-Fes tyrosine kinase activity by coiled-coil and SH2 domains: analysis with Saccharomyces cerevisiae. Biochemistry (2003) 0.91

A network solution. Nature (2008) 0.90

BDNF promotes target innervation of Xenopus mandibular trigeminal axons in vivo. BMC Dev Biol (2007) 0.89

The chemokine interleukin-8 and the surface activation protein CD69 are markers for Bcr-Abl activity in chronic myeloid leukemia. Mol Oncol (2008) 0.89

Viperin is an iron-sulfur protein that inhibits genome synthesis of tick-borne encephalitis virus via radical SAM domain activity. Cell Microbiol (2013) 0.88

Spatially restricted translation of the xCR1 mRNA in Xenopus embryos. Mol Cell Biol (2009) 0.87

A computational approach to analyze the mechanism of action of the kinase inhibitor bafetinib. PLoS Comput Biol (2010) 0.85

Affinity purification strategies for proteomic analysis of transcription factor complexes. J Proteome Res (2013) 0.85

Deconvolution of targeted protein-protein interaction maps. J Proteome Res (2012) 0.85

Systems biology analysis of protein-drug interactions. Proteomics Clin Appl (2011) 0.84

Report on EU-USA workshop: how systems biology can advance cancer research (27 October 2008). Mol Oncol (2008) 0.84

Dishevelled limits Notch signalling through inhibition of CSL. Development (2012) 0.84

Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRalpha. Exp Hematol (2008) 0.83

Charting protein complexes, signaling pathways, and networks in the immune system. Immunol Rev (2006) 0.83

A miniaturized chemical proteomic approach for target profiling of clinical kinase inhibitors in tumor biopsies. J Proteome Res (2013) 0.81

Protein interaction networks in innate immunity. Trends Immunol (2013) 0.81

After the grape rush: sirtuins as epigenetic drug targets in neurodegenerative disorders. Bioorg Med Chem (2011) 0.81

Drugs in action. Nat Chem Biol (2008) 0.81

Reciprocal stabilization of ABL and TAZ regulates osteoblastogenesis through transcription factor RUNX2. J Clin Invest (2016) 0.80

Targeting allosteric regulatory modules in oncoproteins: "drugging the undruggable". Oncotarget (2011) 0.80

High-affinity Src-SH2 ligands which do not activate Tyr(527)-phosphorylated Src in an experimental in vivo system. Biochem Biophys Res Commun (2002) 0.80

Corrigendum: The promise and peril of chemical probes. Nat Chem Biol (2015) 0.79

A functional genome-wide in vivo screen identifies new regulators of signalling pathways during early Xenopus embryogenesis. PLoS One (2013) 0.79